Microbot Medical (NASDAQ:MBOT - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.07, Zacks reports.
Microbot Medical Trading Up 3.5%
NASDAQ:MBOT traded up $0.09 during trading hours on Monday, reaching $2.66. 1,026,482 shares of the company traded hands, compared to its average volume of 2,271,679. The business's 50-day moving average price is $2.14 and its two-hundred day moving average price is $1.70. Microbot Medical has a 1 year low of $0.82 and a 1 year high of $3.38. The stock has a market capitalization of $96.77 million, a P/E ratio of -3.32 and a beta of 1.15.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Microbot Medical stock. Goldman Sachs Group Inc. purchased a new stake in shares of Microbot Medical Inc. (NASDAQ:MBOT - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 37,744 shares of the biotechnology company's stock, valued at approximately $57,000. Goldman Sachs Group Inc. owned about 0.11% of Microbot Medical as of its most recent SEC filing. Institutional investors and hedge funds own 16.30% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Microbot Medical in a research note on Thursday, April 10th.
Get Our Latest Report on Microbot Medical
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Featured Articles

Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.